Magnesium Research · 2017 · 11 citations · 0 references
PharmacyPediatricsPharmacotherapyPediatric DisabilityPediatric NeurologyPediatric PharmacotherapyAnxiety DisordersHeadache AssessmentHeadache ManagementMigraine PharmacotherapyPediatric Clinical TrialsPediatric Headache ManagementHeadache ProphylaxisLong-term ProphylaxisMigraine ProphylaxisPediatric Migraine ManagementPreventive Migraine TherapyPreventive Migraine TreatmentPsychosocial Well-beingWell-being
) = 8.91 (1.59, 49.29), p = 0.001). Considering the KIDSCREEN-27, scores for physical and psychological well-being and social support domain significantly increased from baseline to end-point (p≤0.01). After 6 months of magnesium prophylaxis, disability due to migraine significantly decreased, whereas physical and psychosocial well-being improved. Children also reported fewer anxiety and depressive symptoms. More follow-up and randomized controlled clinical trials are needed to propose clinical recommendations for magnesium prophylaxis in pediatric migraine.